Taylor Wirth, Partner at Barnes & Thornburg Life science companies, particularly those heavily invested in research and development, often face critical funding decisions. Should they
What You Should Know: – Bluespine, an AI-driven claims cost reduction platform for self-insured employers, has secured $7.2M in seed funding to address the pervasive
What You Should Know: – NEC X, the Silicon Valley venture studio backed by NEC’s portfolio of advanced technologies and global businesses, today announced a new
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: 23andMe said Monday it will
Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. Sequel Medtech is working to sell a
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Livanova said Monday a trial
Two senior Biden administration officials on Wednesday warned there could be serious consequences for the nation’s children if it had to relearn lessons about the
AYR Wellness Reports Third Quarter 2024 Results MIAMI, Nov. 13, 2024 (GLOBE NEWSWIRE) — AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”),
Sen. John Thune (R-S.D.), the newly elected Senate majority leader, is big on telehealth, rural hospitals, and increasing transparency for drug middlemen. As majority leader,
The AUGMENT-101 trial evaluated the safety and efficacy of revumenib in adults with relapsed or refractory mutant NPM1 AML. Credit: SeventyFour via Shutterstock. Syndax Pharmaceuticals